Skip to main content
. 2022 Jan 27;12(2):326. doi: 10.3390/diagnostics12020326

Table 2.

Clinical features.

Case No. Age (yrs) Presenting Symptom Imaging Finding CA 125 (U/mL) CA 19-9 (U/mL) Clinical Impression Surgical Treatment Adjuvant Treatment Recurrence Treatment for Recurrence DFS (mos) Status OS (mos)
1 42 Pelvic mass 7.4-cm cystic right ovarian mass with internal solid nodules 72.5 80.1 Ovarian clear cell carcinoma TH with BSO, PLND, PALND, peritonectomy, and omentectomy (PDS) Lung, liver, and peritoneum PLND, PALND, peritonectomy, omentectomy, appendectomy, and hepatectomy (SDS), and chemotherapy 13 Dead 39
2 53 4.8-cm cystic left ovarian mass with small enhancing nodules 26.8 NA Ovarian borderline tumor or carcinoma TH with BSO, PLND, peritonectomy, and omentectomy (PDS) Chemotherapy 21 Alive (NED) 21
3 57 Abdominal distension 10.9-cm cystic left ovarian mass with solid component 12.2 25.4 Ovarian borderline tumor or carcinoma BSO with PLNS, peritonectomy, and omentectomy (PDS) Chemotherapy 11 Alive (NED) 11
4 61 Pelvic mass Solid and cystic left ovarian mass showing intense hypermetabolic activity NA NA Ovarian carcinoma TH with BSO, PLND, PALND, peritoneal biopsy, and omentectomy (PDS) Chemotherapy NA (follow-up loss) NA NA NA NA
5 52 Pelvic mass 5.8-cm solid mass involving the right lateral uterine wall 108.8 9.3 Uterine leiomyoma or LMS TH with BSO and peritonectomy (PDS) Chemotherapy 53 Alive (NED) 53

Abbreviations: BSO, bilateral salpingo-oophorectomy; CA 19-9, cancer antigen 19-9; CA 125, cancer antigen 125; DFS, disease-free survival; LMS, leiomyosarcoma; mos, months; NA, not applicable; NED, no evidence of disease; OS, overall survival; PALND, para-aortic lymph node dissection; PDS, primary debulking surgery; PLND, pelvic lymph node dissection; PLNS, pelvic lymph node sampling; SDS, secondary debulking surgery; TH, total hysterectomy; yrs, years; –, absent.